PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model.

UC-1V150 is a specific TLR7 (Toll-like receptor) agonist that stimulates cellular immune responses and has anti-tumor activity. UC-1V150 can be used to synthesize ISAC (Immune-Stimulating Antibody Conjugates) molecule.

Agatolimod (ODN 2006), a class B ODN (oligodeoxynucleotide), is a TLR9 agonist. Agatolimod is also an optimal CpG sequence for humans. Agatolimod stimulates very strong production of NO2 and IL-6 in HD11 cells. Agatolimod can be used for breast cancer research. Sequence: 5'-tcgtcgttttgtcgttttgtcgtt-3'.

ODN 1826, a class B ODN (oligodeoxynucleotide), is a TLR9 agonist. CpG ODN 1826 is an excellent immunostimulator that induces NO and iNOS production in the murine model. CpG ODN 1826 enhances cell apoptosis. ODN 1826 sequence: 5’-tccatgacgttcctgacgtt-3’.

Topramezone is a potent 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) inhibitor. Topramezone is a herbicide, used for the post-emergence control of broadleaf and grass weeds in corn.

Loxoprofenol-SRS tromethamine (HR1405-01), an active metabolite of Loxoprofen, is a Safe intravenous non-steroidal anti-inflammatory drug (NSAID) with superior anti-inflammatory and analgesic activities.

Amgen-23 (compound 23) is a potent sphingosine kinases (SPHK) inhibitor with IC50 values of 20 nM and 1.6 μM for SPHK1 and SPHK2, respectively. Amgen-23 can be used for researching anticancer.

Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases.

Edecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research.

Vipoglanstat (BI 1029539, GS-248), a carboxamide, is a potent and selective, non-peptide and orally active small molecular inhibitor of human prostaglandin E synthase 1 (mPGES-1). Vipoglanstat (BI 1029539, GS-248) also has anti-inflammatory activity.

CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production.

ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a TLR9 agonist. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3'.

ODN 24888 is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 involves in immune and inflammatory responses, can be used as a vaccine adjuvant.

ODN 24991, a guanine-modified inhibitory oligonucleotide (INH-ODN), is a TLR3, TLR7 and TLR9 (Toll-like receptor) inhibitor, and its parent is INH-ODN 2088. ODN 24991 disrupts TLR3-, TLR7- and TLR9-mediated immune cell immune responses. ODN 24991 sequence: 5'-C-C-T-G-G-C-c7rGm-G-G-G-3'.

ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3'.

ODN M362, a class C oligodeoxynucleotide, is a TLR-9 agonist and can be used as a vaccine adjuvant. ODN M362 induces cancer cell apoptosis.

ODN TTAGGG (A151), inhibitory oligonucleotide (ODN), is a TLR9, AIM2 and cGAS antagonist. ODN TTAGGG is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.

Epoetin delta is a recombinant human erythropoietin. Epoetin delta could protect human renal tubular epithelial cells against oxidative stress by a dose-dependent inhibition of reactive oxygen species (ROS) formation. Epoetin delta can be used for the research of anaemia and kidney diseases. Epoetin Delta also exhibits antifibrotic activity in the remnant kidney rat model.

o-Hydroxybenzylamine (2-HOBA) a selective dicarbonyl scavenger, is an antioxidant and scavanger of free radicals and isolevuglandins (IsoLGs). o-Hydroxybenzylamine can be used in the research of inflammation and cardiovascular disease, such as atherosclerosis, early recurrence of atrial fibrillation (AF) and arrhythmias.

Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis.

Indomethacin (Indometacin) sodium is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium has anticancer activity and anti-infective activity. Indomethacin sodium can be used for cancer, inflammation and viral infection research..

NDT-30805 is a selective NLRP3 inflammasome inhibitor. NDT-30805 is a triazolopyrimidinone derivative and inhibits IL-1β release in PBMCs with an IC50 of 0.013 μM. NDT-30805 can be used for the research of inflammation and innate immunity.

TAK-676 is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. TAK-676 is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. TAK-676 promotes durable IFN-dependent antitumor immunity.

BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 can selectively stimulate the STING pathway. BSP16 can be used for the research of cancer.

KTX-497 is a IRAK4 degrader with a DC50 value of 3 nM. KTX-497 can be used for the research of oncology.

KTX-612 is an orally active IRAK4 degrader with a DC50 value of 7 nM. KTX-612 can be used for the research of oncology.

KTX-582 is a potent IRAK4 degrader with DC50 values of 4 nM and 5 nM for IRAK4 and Ikaros, respectively. KTX-582 can induce apoptosis in MYD88MT DLBCL, and is efficient to induce in vivo tumor regressions in lymphoma model.

MnTE-2-PyP (BMX-010) chloride is a ROS scavenger and potent radioprotector. MnTE-2-PyP also is a manganese porphyrin, protects normal prostate tissue from radiation damage. MnTE-2-PyP can be used for the research of diabetic prostate cancer.

GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation.

Romurtide (Muroctasin), a synthetic muramyl dipeptide derivative, is a cytokines inducer. Romurtide can increase peripheral neutrophils and monocytes in vivo and enhance production of colony-stimulating factors (CSFs), IL-1 and IL-6 in vitro.

CP-447697 is a lipophilic C5a receptor antagonist with an IC50 value of 31 nM. CP-447697 can be used for the research of inflammation.

KTX-955 is a potent IRAK4 degrader with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively. KTX-955 can be used to research anticancer.

CDN-A is a cyclic di-nucleotide, it can be used to synthesis antibody-drug conjugate (ADC). Cyclic di-nucleotides are potent stimulators of innate and adaptive immune responses. In humans, cyclic di-nucleotide, which are either produced endogenously in response to foreign DNA or by invading bacterial pathogens, trigger the innate immune system by activating the expression of interferon genes.

TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research.

CM-H2DCFDA is a derivative of H2DCFDA. CM-H2DCFDA can be used to determine cellular oxidant levels (Ex/Em: 495/530 nm). CM-H2DCFDA is light-sensitive.

Mal-Pc is a versatile molecular photosensitizer designed based phthalocyanine and maleimides. Mal-Pc can react with GSH to deplete GSH and reduce aggregation, thereby improving ROS (Reactive Oxygen Species)-mediated effect of photodynamic therapy (PDT) in cancer cells.

Pifoxime is a COX-1/2 inhibitor, a non-steroidal anti-inflammatory agent (NSAID). Pifoxime shows anti-inflammatory activity, and can be used in neuropsychiatric research.

PPOH, a fatty acid derivative, is a selective < a href=" " class="link-product" target="_blank">cyclooxygenase inhibitor that inhibits arachidonic acid cyclooxygenase activity in renal cortical microsomes. In addition, PPOH acts on CYP4A2 and CYP4A3 with the IC50 values of 22 μM and 6.5 μM, respectively.

Myelopeptide-2 is a peptide originally isolated from the supernatant of porcine bone marrow cell cultures, can restore mitogenic reactivity of human T lymphocytes inhibited by HL-60 leukemia cells or measles virus conditions. Myelopeptide-2 also recover depressed interleukin-2 (IL-2) synthesis and interleukin-2 receptor (IL-2R) expression. Myelopeptide-2 involves in immunity homeostasis, is perspective to be applied in antitumor and antivirus research.

BMS-37 is a PD-1/PD-L1 immune checkpoint inhibitor. BMS-37 can be used as PD-L1 ligand to synthesize PROTAC molecules.

CL845-PAB-Ala-Val-PEG4-Azide is a conjugatable STING ligand， it is synthesized from the proprietary cyclic dinuleotide CL845. CL845-PAB-Ala-Val-PEG4-Azide can be used for bioconjugation.

CL845-PAB-Ala-Val-C5-MC is a conjugatable STING ligand， it is synthesized from the proprietary cyclic dinuleotide CL845. CL845-PAB-Ala-Val-C5-MC can be used for bioconjugation.

C-di-IMP (Cyclic-di-IMP) is a STING agonist. C-di-IMP can be used for the research of tumor.

CL845 is an analog of the STING agonist CL656. CL845 can be used to synthesize conjugatable PRR ligands that target STING (stimulator of interferon genes). CL845 can be usexd for the research of cancers, immunological disorders or infections.

QD394 is a reactive oxygen species (ROS) inducer that can induce lipid peroxidation, increase intracellular ROS accumulation, inhibit STAT3 phosphorylation, and induce ferroptosis.

Denileukin diftitox (DAB 389IL-2) is a diphtheria toxin (DT)-related interleukin 2 (IL-2) fusion protein toxin that depletes cells expressing the high-affinity form of the IL-2 receptor (IL-2R), CD25. Denileukin diftitox binds to cells expressing IL-2R and inhibits protein synthesis through internalization of the diphtheria toxin fragment.

OSM-SMI-8 (NSC642624) is a potent OSM (oncostatin M) antagonist. OSM-SMI-8 has the potential for the research of cancer.

Didocosahexaenoin, an omega-3 derivative, is a diglyceride of DHA and can be synthesised from DHA triglycerides. Didocosahexaenoin causes significant loss of mitochondrial membrane potential and induces ROS production. Didocosahexaenoin induces apoptosis. Didocosahexaenoin induces stronger cytotoxicity than DHA in human prostate carcinoma cells.

RDR 02308 is a TLR4-MyD88 binding inhibitor that inhibits full-length β-lactamase.

STING agonist-22 (CF501) is a potent non-nucleotide STING agonist. STING agonist-22 is a adjuvant by activating STING to induce the type I interferon (IFN-I) response and proinflammatory cytokine production. STING agonist-22 can be used as an adjuvant to boost the original protein vaccine, producing potent, broad, and long-term immune protection. STING agonist-22 can be used for SARS-CoV-2 variants and sarbecovirus diseases research.

BW 755C is a 5-lipoxygenase (5-LO) inhibitor with an IC50 of 5 μM. BW 755C also inhibits cyclooxygenase (COX) with IC50s of 0.65 and 1.2 μg/mL against COX-1 and COX-2, respectively.

Enpatoran (M5049) hydrochloride is a potent, orally active, and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM, respectively, in HEK293 cells.

AHR-10037 is a non-steroidal anti-inflammatory agent with low gastric toxicity. AHR-10037 is a prodrug converted in vivo to a cyclooxygenase inhibitor.

ODN 4084-F is a class B (‘broadly-active’) inhibitory ODN. ODN 4084-F is potent inhibitor of TLR9-induced B cells and macrophages.

ODN 5328 (ODN 2395 Control) can be used as a sequence control for C-class ODN 2395. ODN 5328 shares the sequence with ODN 2395 but contain GpC dinucleotides instead of the CpG motifs.

NVS-STG2 is a small molecule STING agonist with AC50 of 5.2 μM. NVS-STG2 induces the high-order oligomerization of human STING by binding to a pocket between the transmembrane domains of the neighboring STING dimers and elicit potent STING-mediated immune responses in cells and antitumor activities in animal models.

CMP-1611 is a small molecule inhibitor of protease of the complement classical pathway, C1r, directly inhibits classical pathway-specific complement activation in a dose-dependent manner.

DF3016A (DF 3016A) is a potent and selective C5aR inhibitor with IC50 of 50 nM (C5a-induced human PMN migration and IC50 of 45 and 37 nM against rat and mouse C5aR, respectively.

T-ALZ01 (CMP-1696) is a small molecule inhibitor of complement component C1r.

Peptide WWGKKYRASKLGLAR is a super agonist of complement factor C3aR, 12-15 times more active than natural C3a.

MK-886 (L-663,536) is a potent, selective and orally active inhibitor of 5-lipoxygenase-activating protein (FLAP) with IC50 of 30 nM.

Rytvela (Peptide 101.10) is a potent, selective, allosteric negative modulator (antagonist) of IL-1 receptor I (IL-1RI), inhibits dose-dependently IL-1-induced PGE2 formation (IC50= 0.5 nM) and IL-1-induced human thymocyte (TF-1 cell) proliferation (IC50=

KME-2780 (KME2780) is a potent and selective dual IRAK1 and IRAK4 (IRAK1/4) inhibitor with IC50 of 19 and 0.5 nM, respectively.

KME-3859 is a potent, selective IRAK4 inhibitor with IC50 of 5 nM, 100-fold selective over IRAK1.

TJ-M2010-2 is a small molecule inhibitor of MyD88 homodimerization, interacts with MyD88 TIR domain.

PCC-0105002 is a novel small molecule inhibitor of PSD95-nNOS protein-protein interaction with IC50 of 1.4 uM.

T1059 is a selective inhibitor of eNOS/iNOS with a long-term vasoconstrictive effect in vivo.

ADS032 (ADS-032) is the first, reversible and stable dual NLRP1 and NLRP3 inflammasome inhibitor, inhibits nigericin-induced NLRP3-induced IL-1β secretion from LPS-primed iBMDMs with IC50 of 30 uM.

DFV890 (IFM-2427) is apotent, selective and orally active inhibitor of NLRP3 inflammasome, directly binds to NLRP3 and locks the protein in an inactive conformation,prevents NLRP3 inflammasome assembly in response to sterile danger signals.

FK156 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

FK565 is an immunoactive peptide and a nucleotide-binding oligomerization domain (Nod)-1 ligand agonist.

JC2-11 is an anti-inflammasome compound and a pan-inhibitor of the NLRP3, NLRC4, and AIM2 inflammasomes.

JT001 (JT-001) is a potent, highly specific NLRP3 inhibitor, inhibits NLRP3 inflammasome assembly.

JT002 is a potent and selective inhibitor of NLRP3 inflammasome with IC50 of 6 nM (IL-1β production from hPBMCs), inhibits NLRP3 mediated cytokine production and pyroptosis.

ML146 (ML-146, Pubmed CID-1088438) is a selective small molecule NOD1 inhibitor with IC50 of 1.5 uM in NOD1 agonist-stimulated NF-κB reporter assay in HEK293T cells.

NDT-19795 is the carboxylic acid metabolite of selective NLRP3 inhibitor NT-0796, suppresses release of IL-1β in LPS-activated human PBMCs with IC50 of 47 nM.

NLRP3-inhibitory compound 7 (NIC7) is a small-molecule inhibitor of Nod-like receptor family pyrin domain-containing 3 (NLRP3), inhibits NLRP3-mediated activation of caspase 1 along with the secretion of IL-1β, IL-18, and lactate dehydrogenase.

NP3-146 is a small molecule NLRP3 inflammasome inhibitor and an analog of MCC950.

ZYIL1 is an oral small molecule NLRP3 inflammasome inhibitor, exhibits potent (IC50 in nanomolar range) in human whole blood and supresses inflammation caused by the NLRP3 inflammasome.

BMS135 is a small molecule h-PD1/h-PD-L1 interaction inhibitor with IC50 of 79.1 nM, bind specifically to hPD-L1 through a unique mode of action, induces the dimerization of hPD-L1.

BMS136 is a small molecule h-PD1/h-PD-L1 interaction inhibitor with IC50 of 96.7 nM, bind specifically to hPD-L1 through a unique mode of action, induces the dimerization of hPD-L1.

IMMH-010 (YPD-30) is an ester prodrug of YPD-29B, a high potent PD-L1 inhibitor (IC50=0.08 pM), YPD-30 is a potent PD-L1 inhibitor with IC50 of 45.2 nM in HTRF assays.

IMMH-010 maleate (YPD-30) is an ester prodrug of YPD-29B, a high potent PD-L1 inhibitor (IC50=0.08 pM), YPD-30 is a potent PD-L1 inhibitor with IC50 of 45.2 nM in HTRF assays.

MAX10181 (MAX-10181) is an orally active small molecule PD-L1 inhibitor, shows similar efficacy as Durvalumab in the head to head test of human PD-L1 knock-in MC38 cell line in human PD-1 knock-in mice.

YPD-29B is a potent, specific programmed cell death ligand 1 (PD-L1) inhibitor, effectively blocks the binding of PD-1 and PD-L1 with IC50 of 0.08 pM in HTRF protein-protein interaction assays.

LY3023703 is a potent, highly selective microsomal prostaglandin E synthase 1 (mPGES1) inhibitor, dose-dependently inhibits PGE2 production in human whole blood ex vivo.

MPO-0144 (MPO 0144) is a potent, selective mPGES-1 inhibitor (PGE2 IC50=41.77 nM, mPGES-1 IC50=1.16 nM), exhibits potent neuroprotection (ED50=3.0 nM) against 6-OHDA-induced in PC12 cells without significant neurotoxicity (IC50>10 uM).

SZ0232 is a small molecule mPGES-2 (microsomal prostaglandin E synthase-2) inhibitor with IC50 of <1 uM, exhibits beneficial effects on modulating β-cell function and glucose metabolism both in vitro and in vivo.

TAS-204 (TAS204) is a potent, specific hematopoietic prostaglandin D synthase (H-PGDS) inhibitor, inhibits recombinant human H-PGDS with IC50 of 24.0 nM.

TAS-205 (Pizuglanstat, TAS205) is a potent, specific hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 of 55.8 nM, does not inhibit LPGDS at 100 uM.

UT-11 is a potent microsomal prostaglandin E synthase-1 (mPGES-1) inhibitor, inhibits PGE2 production from human SK-N-AS and murine BV2 cells induced by LPS with IC50 of 0.1 and 2.0 uM, respectively.

HWG-35D is a potent, selective sphingosine kinase 2 (SphK2, SK2) with IC50 of 41 nM, 100-fold selectivity for SK2 over SK1.

SLL3071511 is a novel potent inhibitor of Chikungunya virus (CHIKV) infection with EC50 of 2.91 uM, inhibits sphingosine kinase SK1 and SK2 with Ki values of 0.27 and 0.66 uM, respectively.

SLP9101555 is a potent, selective sphingosine kinase SphK2 with Ki of 90 nM (hSphK2), 200-fold selectivity over SphK1.

ChX710 (ChX0306710) is a small molecule that primes the type I interferon response to cytosolic DNA, which is dependent on the adaptor MAVS and IRF1, but not the IRF3.

DWL-4-140 is a small molecule inhibitor of cyclized nucleotide-binding domain (CBD) of STING, selectively inhibits DNA-mediated IFNβ responses with IC50 of 617 nM.

HB3089 (HB-3089) is a novel potent, highly specific STING agonist, dose-dependently activates interferon-stimulated gene (ISG) signaling in THP1-Dual reporter cells with EC50 of 1-10 uM.

LB244 (LB-244) is a highly potent, selective and irreversible STING antagonist, blocks STING oligomerization and inhibits STING signaling THP1 dual cells with IC50 of 0.8 uM.

MK-1454 (Ulevostinag) is a novel cyclic dinucleotide STING agonist with robust tumor cytokine upregulation and effective antitumor activity.

SB24011 (SB 24011) is a selective small molecule inhibitor of the STING-TRIM29 interaction with IC50 of 3.85 uM in luciferase complementation assays, enhances cGAMP-mediated STING immunity.

SHR1032 is a novel small molecule non-cyclic di-nucleotide STING agonist, exhibits significantly high affinity binding to STING and cellular reporter assay (EC50=30 nM).

AZD8848 (AZD 8848) is a potent, selective TLR7 agonist with EC50 of 4 nM for induction of IFNα from human PBMCs and an IC50 of 0.2-1.0 nM for inhibition of IL-5.

Diprovocim-X is a potent human and murine TLR1/TLR2 agonist with EC50 of 0.14 nM (hTLR1/TLR2) and 0.75 nM (m TLR1/TLR2), respectively.

E014 is a potent, selective TLR7 agonist with EC50 of 69 nM in Ramos Blue reporter assays, >500-fold selective for TLR7 over TLR8.

E567 is a small moleculeTLR2 signaling inhibitor with anti-viral activity, efficiently inhibits both LCMV and HSV-1 induced cytokine responses in both human and mouse cell cultures.

E6742 (E6742) is a potent, selective, dual TLR7/8 inhibitor with binding Kd of 1.7 uM/37 nM in ITC assays, respectively, inhibits TLR7/8 agonist CL097 induced reporter activation with IC50 values of 22, 68, and 3.0 nM for hTLR7, mTLR7, and hTLR8, respecti

MHV370 (MHV-370) is a potent, selective, orally bioavailable inhibitor of Toll-like receptors 7 and 8 (TLR7/8) with IC50 of 1.1 and 4.5 nM in cell-based assays.

SZU101 is a small molecule TLR7 agonist that directly activates, induces reporter activity (23-fold) in a TLR7-NF-kB reporter system expressed in HEK-293 cells TLR7 signalling.

SZU-106 is a small molecule TLR7 agonist, selectively activates TLR7 and increases the expression of SEAP by activating the NF-κB pathway.